NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT00356122 2011-10-17Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)SanofiPhase 2 Completed53 enrolled 14 charts